Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2022 | $4.00 | Buy | Canaccord Genuity |
| 10/14/2022 | $5.50 | Outperform | Credit Suisse |
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)
SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)
SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)
Canaccord Genuity initiated coverage of GreenLight Biosciences with a rating of Buy and set a new price target of $4.00
Credit Suisse initiated coverage of GreenLight Biosciences with a rating of Outperform and set a new price target of $5.50
LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced the closing of its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent"), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the "Merger"). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the "NASDAQ") before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each r
LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (
NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of GRNA to a group of buyers led by Fall Line Capital, LLC for $0.30 per share in cash. If you are a GRNA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Arlington Asset Investment Corp. (NYSE:AAIC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connect
GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (i) owned by GreenLight as treasury stock (ii) owned by
Upgrades For The Carlyle Group Inc (NASDAQ:CG), Raymond James upgraded the previous rating of Market Perform to Outperform. For the first quarter, Carlyle Group had an EPS of $0.63, compared to year-ago quarter EPS of $0.74. The stock has a 52-week-high of $40.73 and a 52-week-low of $24.61. At the end of the last trading period, Carlyle Group closed at $28.15. Piper Sandler upgraded the previous rating for Akebia Therapeutics Inc (NASDAQ:AKBA) from Neutral to Overweight. In the first quarter, Akebia Therapeutics showed an EPS of $0.14, compared to $0.35 from the year-ago quarter. The current stock performance of Akebia Therapeutics shows a 52-week-high of $1.63 and a 52-week-low of $0.24
Canaccord Genuity analyst Bobby Burleson downgrades GreenLight Biosciences (NASDAQ:GRNA) from Buy to Hold and lowers the price target from $4 to $0.3.
15-12G - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)
8-K/A - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)
EFFECT - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)
LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (